{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:01Z","timestamp":1787729401287,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dopamine receptors are G protein-coupled transmembrane proteins that mediate dopamine-dependent neurotransmission in the central nervous system via intracellular signaling cascades. Through their involvement in motor and cognitive processes, they are involved in various neurological diseases and their symptoms, including Parkinson\u2019s disease and schizophrenia. The pharmacological modification or antagonization of dopamine receptors is therefore highly relevant. Dopamine receptors have been studied across diverse conditions, yet the resulting clinical evidence is scattered and highly heterogeneous, with no structured synthesis to date. This fragmentation limits the ability to evaluate the broader clinical relevance of dopamine receptor modulation, and a synthesis of these heterogenous trials represents a research gap. By systematically mapping and summarizing available trials, this review provides an integrated overview and highlights areas where further research is needed. The aim of this scoping review was to analyze current and completed clinical studies on dopamine receptors. Because the field of dopamine receptor\u2013targeted therapies is broad, complex, and not yet systematically mapped, a scoping review offers the methodological flexibility to capture this diversity and synthesize current knowledge. ClinicalTrials.gov was searched for trials on dopamine receptors. Studies with a focus on any dopamine receptor were included, while studies employing dopamine receptors and related medications as comparators were excluded. Search results were evaluated based on the condition, the type of intervention, the study location, the sponsor, and the outcome. Two hundred forty-five. trials on dopamine receptors were identified. One hundred ninety-two (78.4%) trials were interventional trials and 53 (21.6%) were observational studies. Ten trials were terminated before completion. More than one-third of the studies (38.3%) were conducted in the USA. Most trials (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009151) were sponsored by sponsors other than industrial or governmental entities, primarily by clinics and medical centers of universities. The most frequent indication was schizophrenia (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920, 8.0%), followed by Parkinson\u2019s disease (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918, 7.2%), tobacco abuse (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098, 3.2%), alcoholism (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097, 2.8%), and other substance abuse (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097, 2.8%). Thirty-eight trials (15.5%) were classified as \u201cHas results,\u201d while for 207 trials (84.5%), no results were available. Of the trials with results, 17 had publications in which the results were reported, with 20 studies published in total. While numerous trials have been conducted on dopamine receptors, the outcome from these studies in terms of scientific publications is low. The reasons for this low output must be investigated in future studies.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04710-x","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:58:53Z","timestamp":1760680733000},"page":"4169-4191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of clinical trials on drugs\u00a0targeting dopamine receptors: a scoping review"],"prefix":"10.1007","volume":"399","author":[{"given":"Thomas","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"4710_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj\u00e4rvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 4:595\u2013604","journal-title":"Lancet Psychiatry"},{"key":"4710_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","volume":"68","author":"ES Bromberg-Martin","year":"2010","unstructured":"Bromberg-Martin ES, Matsumoto M, Hikosaka O (2010) Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68:815\u2013834","journal-title":"Neuron"},{"key":"4710_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","volume":"211","author":"C Cepeda","year":"2014","unstructured":"Cepeda C, Murphy KP, Parent M, Levine MS (2014) The role of dopamine in Huntington\u2019s disease. Prog Brain Res 211:235\u2013254","journal-title":"Prog Brain Res"},{"key":"4710_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/35065000","volume":"410","author":"L Chang","year":"2001","unstructured":"Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37\u201340","journal-title":"Nature"},{"key":"4710_CR5","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M, Melmed S (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106:e917\u2013e925","journal-title":"J Clin Endocrinol Metab"},{"key":"4710_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1056\/NEJM196907312810517","volume":"281","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R (1969) L-dopa in Parkinson\u2019s syndrome. N Engl J Med 281:272","journal-title":"N Engl J Med"},{"key":"4710_CR7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fneur.2013.00090","volume":"4","author":"R de la Fuente-Fern\u00e1ndez","year":"2013","unstructured":"de la Fuente-Fern\u00e1ndez R (2013) Imaging of dopamine in PD and implications for motor and neuropsychiatric manifestations of PD. Front Neurol 4:90","journal-title":"Front Neurol"},{"key":"4710_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1093\/brain\/awt263","volume":"136","author":"N del Campo","year":"2013","unstructured":"del Campo N, Fryer TD, Hong YT, Smith R, Brichard L, Acosta-Cabronero J, Chamberlain SR, Tait R, Izquierdo D, Regenthal R, Dowson J, Suckling J, Baron JC, Aigbirhio FI, Robbins TW, Sahakian BJ, M\u00fcller U (2013) A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain 136:3252\u20133270","journal-title":"Brain"},{"key":"4710_CR9","first-page":"454","volume":"2","author":"AD DiVasta","year":"2021","unstructured":"DiVasta AD, Stamoulis C, Gallagher JS, Laufer MR, Anchan R, Hornstein MD (2021) Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. F S Rep 2:454\u2013461","journal-title":"F S Rep"},{"key":"4710_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2337\/dc11-2250","volume":"35","author":"JP Dunn","year":"2012","unstructured":"Dunn JP, Kessler RM, Feurer ID, Volkow ND, Patterson BW, Ansari MS, Li R, Marks-Shulman P, Abumrad NN (2012) Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care 35:1105\u20131111","journal-title":"Diabetes Care"},{"key":"4710_CR11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/oby.22023","volume":"25","author":"JP Dunn","year":"2017","unstructured":"Dunn JP, Abumrad NN, Kessler RM, Patterson BW, Li R, Marks-Shulman P, Tamboli RA (2017) Caloric restriction-induced decreases in dopamine receptor availability are associated with leptin concentration. Obesity (Silver Spring) 25:1910\u20131915","journal-title":"Obesity (Silver Spring)"},{"key":"4710_CR12","doi-asserted-by":"publisher","first-page":"e0212738","DOI":"10.1371\/journal.pone.0212738","volume":"14","author":"JP Dunn","year":"2019","unstructured":"Dunn JP, Abumrad NN, Patterson BW, Kessler RM, Tamboli RA (2019) Brief communication: \u03b2-cell function influences dopamine receptor availability. PLoS ONE 14:e0212738","journal-title":"PLoS ONE"},{"key":"4710_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38:1236\u20131239","journal-title":"Klin Wochenschr"},{"key":"4710_CR14","doi-asserted-by":"crossref","unstructured":"Fernstrom JD, Fernstrom MH (2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137: 1539S-1547S; discussion 1548S","DOI":"10.1093\/jn\/137.6.1539S"},{"key":"4710_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF02988639","volume":"16","author":"WG Frankle","year":"2002","unstructured":"Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16:437\u2013446","journal-title":"Ann Nucl Med"},{"key":"4710_CR16","doi-asserted-by":"publisher","first-page":"e0142676","DOI":"10.1371\/journal.pone.0142676","volume":"10","author":"AE Garcia","year":"2015","unstructured":"Garcia AE, Kasim N, Tamboli RA, Gonzalez RS, Antoun J, Eckert EA, Marks-Shulman PA, Dunn J, Wattacheril J, Wallen T, Abumrad NN, Flynn CR (2015) Lipoprotein profiles in class III obese Caucasian and African American women with nonalcoholic fatty liver disease. PLoS ONE 10:e0142676","journal-title":"PLoS ONE"},{"key":"4710_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41386-019-0590-6","volume":"45","author":"RR Girgis","year":"2020","unstructured":"Girgis RR, Forbes A, Abi-Dargham A, Slifstein M (2020) A positron emission tomography occupancy study of brexpiprazole at dopamine D(2) and D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology 45:786\u2013792","journal-title":"Neuropsychopharmacology"},{"key":"4710_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","volume":"179","author":"DC Goff","year":"2005","unstructured":"Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D (2005) A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 179:144\u2013150","journal-title":"Psychopharmacology"},{"key":"4710_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","volume":"48","author":"ID Grachev","year":"2021","unstructured":"Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek F, Rullmann M, Sattler B, Patt M, Gerhards T, Strauss M, Kluge A, Brust P, Savola JM, Gordon MF, Geva M, Hesse S, Barthel H, Hayden MR, Sabri O (2021) Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study. Eur J Nucl Med Mol Imaging 48:1103\u20131115","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4710_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/104012371402600304","volume":"26","author":"JE Grant","year":"2014","unstructured":"Grant JE, Odlaug BL, Black DW, Fong T, Davtian M, Chipkin R, Kim SW (2014) A single-blind study of \u2018as-needed\u2019 ecopipam for gambling disorder. Ann Clin Psychiatry 26:179\u2013186","journal-title":"Ann Clin Psychiatry"},{"key":"4710_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/carcin\/bgac045","volume":"43","author":"CE Grant","year":"2022","unstructured":"Grant CE, Flis AL, Ryan BM (2022) Understanding the role of dopamine in cancer: past, present and future. Carcinogenesis 43:517\u2013527","journal-title":"Carcinogenesis"},{"key":"4710_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(06)78001-1","volume":"78","author":"O Guillin","year":"2007","unstructured":"Guillin O, Abi-Dargham A, Laruelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1\u201339","journal-title":"Int Rev Neurobiol"},{"key":"4710_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72:1491\u20131500","journal-title":"JAMA Neurol"},{"key":"4710_CR24","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP (2005) Why most published research findings are false. PLoS Med 2:e124","journal-title":"PLoS Med"},{"key":"4710_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12883-015-0267-7","volume":"15","author":"JM Kim","year":"2015","unstructured":"Kim JM, Chung SJ, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L (2015) Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson\u2019s disease: an open-label study. BMC Neurol 15:17","journal-title":"BMC Neurol"},{"key":"4710_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","volume":"39","author":"MO Klein","year":"2019","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2019) Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol 39:31\u201359","journal-title":"Cell Mol Neurobiol"},{"key":"4710_CR27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/jnr.24495","volume":"97","author":"ET Koch","year":"2019","unstructured":"Koch ET, Raymond LA (2019) Dysfunctional striatal dopamine signaling in Huntington\u2019s disease. J Neurosci Res 97:1636\u20131654","journal-title":"J Neurosci Res"},{"key":"4710_CR28","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/hmg\/ddl152","volume":"15","author":"D Li","year":"2006","unstructured":"Li D, Sham PC, Owen MJ, He L (2006) Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 15:2276\u20132284","journal-title":"Hum Mol Genet"},{"key":"4710_CR29","first-page":"Mr000033","volume":"2","author":"A Lundh","year":"2017","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:Mr000033","journal-title":"Cochrane Database Syst Rev"},{"key":"4710_CR30","first-page":"1","volume":"10","author":"M Madadi Asl","year":"2019","unstructured":"Madadi Asl M, Vahabie AH, Valizadeh A (2019) Dopaminergic modulation of synaptic plasticity, its role in neuropsychiatric disorders, and its computational modeling. Basic Clin Neurosci 10:1\u201312","journal-title":"Basic Clin Neurosci"},{"key":"4710_CR31","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/S0021-9258(18)93832-9","volume":"239","author":"T Nagatsu","year":"1964","unstructured":"Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239:2910\u20132917","journal-title":"J Biol Chem"},{"key":"4710_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","volume":"24","author":"NS Narayanan","year":"2013","unstructured":"Narayanan NS, Rodnitzky RL, Uc EY (2013) Prefrontal dopamine signaling and cognitive symptoms of Parkinson\u2019s disease. Rev Neurosci 24:267\u2013278","journal-title":"Rev Neurosci"},{"key":"4710_CR33","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1212\/WNL.0b013e31828f18f0","volume":"80","author":"L Norcliffe-Kaufmann","year":"2013","unstructured":"Norcliffe-Kaufmann L, Martinez J, Axelrod F, Kaufmann H (2013) Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa. Neurology 80:1611\u20131617","journal-title":"Neurology"},{"key":"4710_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/mol.108.053017","volume":"75","author":"A Sahu","year":"2009","unstructured":"Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undieh AS (2009) D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol 75:447\u2013453","journal-title":"Mol Pharmacol"},{"key":"4710_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5498\/wjp.v11.i7.355","volume":"11","author":"MV Seeman","year":"2021","unstructured":"Seeman MV (2021) History of the dopamine hypothesis of antipsychotic action. World J Psychiatry 11:355\u2013364","journal-title":"World J Psychiatry"},{"key":"4710_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.biopsych.2019.03.965","volume":"86","author":"PA Spagnolo","year":"2019","unstructured":"Spagnolo PA, Kimes A, Schwandt ML, Shokri-Kojori E, Thada S, Phillips KA, Diazgranados N, Preston KL, Herscovitch P, Tomasi D, Ramchandani VA, Heilig M (2019) Striatal dopamine release in response to morphine: a [(11)C]raclopride positron emission tomography study in healthy men. Biol Psychiatry 86:356\u2013364","journal-title":"Biol Psychiatry"},{"key":"4710_CR37","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2010.08.026","volume":"68","author":"TJ Spencer","year":"2010","unstructured":"Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, Martin J, Fischman AJ (2010) A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [11C]altropane and [11C]raclopride. Biol Psychiatry 68:964\u2013970","journal-title":"Biol Psychiatry"},{"key":"4710_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473","journal-title":"Ann Intern Med"},{"key":"4710_CR39","doi-asserted-by":"publisher","first-page":"53791","DOI":"10.18632\/oncotarget.17339","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, Farhan M, Xu J, Lazarovici P, Zheng W (2017) The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget 8:53791\u201353803","journal-title":"Oncotarget"},{"key":"4710_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/cpdd.1057","volume":"11","author":"T Yamaguchi","year":"2022","unstructured":"Yamaguchi T, Kudou K, Okamoto H, Chen C, Whiting R, Sekino H (2022) Evaluating the safety, tolerability, and disposition of trazpiroben, a D(2)\/D(3) receptor antagonist: phase i single- and multiple-ascending dose studies in healthy Japanese participants. Clin Pharmacol Drug Dev 11:695\u2013706","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4710_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13803395.2023.2187041","volume":"45","author":"M Zack","year":"2023","unstructured":"Zack M, Lobo D, Biback C, Fang T, Smart K, Tatone D, Kalia A, Digiacomo D, Kennedy JL (2023) Priming effects of a slot machine game and amphetamine on probabilistic risk-taking in people with gambling disorder and healthy controls. J Clin Exp Neuropsychol 45:31\u201360","journal-title":"J Clin Exp Neuropsychol"},{"key":"4710_CR42","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s41386-019-0456-y","volume":"44","author":"Y Zakiniaeiz","year":"2019","unstructured":"Zakiniaeiz Y, Hillmer AT, Matuskey D, Nabulsi N, Ropchan J, Mazure CM, Picciotto MR, Huang Y, McKee SA, Morris ED, Cosgrove KP (2019) Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. Neuropsychopharmacology 44:2205\u20132211","journal-title":"Neuropsychopharmacology"},{"key":"4710_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1570159X14666151208114634","volume":"14","author":"J Zhang","year":"2016","unstructured":"Zhang J, Tan LC (2016) Revisiting the medical management of Parkinson\u2019s disease: levodopa versus dopamine agonist. Curr Neuropharmacol 14:356\u2013363","journal-title":"Curr Neuropharmacol"},{"key":"4710_CR44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cell.2021.01.027","volume":"184","author":"Y Zhuang","year":"2021","unstructured":"Zhuang Y, Xu P, Mao C, Wang L, Krumm B, Zhou XE, Huang S, Liu H, Cheng X, Huang XP, Shen DD, Xu T, Liu YF, Wang Y, Guo J, Jiang Y, Jiang H, Melcher K, Roth BL, Zhang Y, Zhang C, Xu HE (2021) Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell 184:931-942.e918","journal-title":"Cell"},{"key":"4710_CR45","doi-asserted-by":"publisher","first-page":"5663274","DOI":"10.1155\/2022\/5663274","volume":"2022","author":"T Zorick","year":"2022","unstructured":"Zorick T, Okita K, Renard KB, Mandelkern MA, Brody AL, London ED (2022) The effects of citalopram and thalamic dopamine D(2\/3) receptor availability on decision-making and loss aversion in alcohol dependence. Psychiatry J 2022:5663274","journal-title":"Psychiatry J"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04710-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:02:41Z","timestamp":1772780561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04710-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4710"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04710-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was carried out in accordance with the guidelines of good scientific practice of Hannover Medical School (\n                      \n                      ) and officially registered as a doctoral project for Thomas Rajan. Hannover Medical School follows the guidelines of the German Research Foundation (DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to declare.\u00a0R.S. in the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable, as publicly available information is used as a data source.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publication consent"}}]}}